Has filgotinib been launched in China?

Filgotinib (Filgotinib) is a new type of oral drug that is a Janus kinase inhibitor (JAk inhibitor) and is mainly used to treat moderate to severe rheumatoid arthritis and other autoimmune diseases. The JAK signaling pathway plays a key role in a variety of inflammatory reactions. Figotinib reduces the inflammatory reactions and symptoms associated with rheumatoid arthritis by inhibiting the activity of Janus kinase. Rheumatoid arthritis is a chronic autoimmune disease in which patients often suffer from joint pain, swelling, and dysfunction, seriously affecting quality of life.

Figotinib was approved by the European Medicines Agency (EMA) and the Japanese Medicines and Medical Devices Agency (PMDA) in 2020, marking its gradual entry into the market globally. In Europe, the drug was approved on September 24, 2020, and in Japan, marketing authorization was also obtained during the same time period. These approvals provide new hope for adult rheumatoid arthritis patients in need of effective treatment options.

In clinical trials, filgotinib has shown significant results in improving patients' joint symptoms. The study results show that a considerable number of patients who use the drug are able to achieve at least 20% improvement in symptoms, which to a certain extent proves its efficacy and safety. In addition, the oral administration method of filgotinib makes the treatment process more convenient for patients. Compared with traditional injection treatment methods, patients have higher compliance and a better use experience.

As for the marketing status of filgotinib in China, as of the current information, it has not yet been officially approved by the China National Medical Products Administration. However, as attention on autoimmune diseases such as rheumatoid arthritis increases, the drug may be launched in the domestic market in the future to further enrich treatment options.

Reference materials:https://everyone.org/jyseleca-filgotinib